Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B7-related protein 1 (B7RP-1), also known as ICOS Ligand (ICOS-L) or CD275, is a type I transmembrane glycoprotein belonging to the B7 family of immune-regulatory ligands and immunoglobulin superfamily. It primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, macrophages/monocytes, and some activated B cells, where it interacts with its receptor, ICOS, on activated T cells. This interaction provides a crucial co-stimulatory signal for T cell activation, differentiation (especially Tfh cells), germinal center formation, and antibody production. As such, B7RP-1 is an area of focus in immunotherapy, with potential applications in enhancing anti-tumor immunity and vaccine efficacy. However, dysregulation may contribute to autoimmune diseases by causing excessive immune responses. Therefore, therapeutic targeting requires careful consideration of potential safety concerns related to immune-related adverse events and exacerbation of autoimmunity.
Modulation of T cell activation via ICOS receptor binding; enhancement or suppression of immune responses
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7-related protein 1 (B7RP-1).